AZD1775 Plus Chemotherapy in Advanced Squamous Cell Lung Cancer

Title: A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer

Principal Investigator: Jhanelle Gray, MD, of H. Lee Moffitt Cancer Center and Research Institute

Description: Researchers are conducting a phase 2 trial of the WEE1 inhibitor AZD1775 in combination with carboplatin and paclitaxel for patients with advanced/metastatic squamous cell lung cancer.

In each 21-day treatment cycle, patients will receive AZD1775, carboplatin, and paclitaxel twice daily on days 1 and 2 and once on day 3, for a total of 5 doses per cycle. 

The primary outcome is progression-free survival. Secondary outcomes include overall survival, duration of overall response and stable disease, and disease control rate.

To be eligible for this study, patients must be 18 years of age and older. They must have advanced/metastatic squamous cell lung cancer with no known curative treatment options. For a complete list of eligibility criteria, please see the reference.

Status: Recruiting

This study is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Reference

ClinicalTrials.gov. AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer. NCT02513563. Accessed July 22, 2022. 

This article originally appeared on Cancer Therapy Advisor